MAGEA3 and cancer: ACT with NY-ESO-1 specific CD4+ T cells were used to successfully treat metastatic melanoma47 and ACT with CD4+ T cells genetically engineered to express an MHC-II–restricted T cell receptor specifically recognizing the cancer germline antigen MAGE-A3 demonstrated clinical efficacy48.